Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5335_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
30.08.2026
Размер:
45 Мб
Скачать
422
Manufacture and Supply, Science and Reg ulation Towards High-Qua lity Medicinal Products
Table 3: Proposed regulatory framework for hand sanitizers
Listing or
certification
Claims and
advertise­ments
Labelling
Sale and supply Should not be sold in bulk packs
Manufacturers must submit application, detailing test methods and results, GMP compliance status, and intended packaging and labels
A listing or certification number is given after approval by RAs
Exemption or expedited review is allowed for those formu­lations and concentrations recommended by WHO, USP and CDC. Only packaging, labels and advertising claims need to be submitted
Prohibit claims on therapeutic indications
Prohibit claims that are false or misleading regarding the
formulation, eectiveness and safety of the product
Advertisements do not require an advertiser’s license, how­ever, should only be limited to their own company websites so that consumers self-initiate the search themselves
Main label must contain the active ingredient(s), concentra­tion and units, expiry date
Must include cautionary labels relating to flammability of ABHS and methanol toxicity
Can only claim eectiveness against test organisms that have been studied
Prohibit labelling claims of 99.9% kill
Prohibit peel-back labels which are labels that have addi-
tional information below the exposed label
Texts should not be too small, crowded and cluttered
Should not be enclosed in bottles or containers resembling
food packages
placed in the market. Product licensing or registration is not always feasible as it can severely increase regulatory costs. Therefore, the proposed idea balances the current lack of regulatory oversight ver­sus over-regulation and increasing compliance costs. Moreover, to
Hand Sanitizers
safeguard consumers, sale in bulk volumes/packs should be prohib­ited, hand sanitizers should not be enclosed in bottles resembling food packaging and cautionary labels should be mandatory. Reg­ulations should also include the need to perform the ecacy tests (Section 4) and to seek approval by RAs to ensure eectiveness of hand sanitizers. Additionally, it is important to prevent consumer misinformation by restricting advertisements to company websites, prohibiting unfounded claims and labelling of a blanket claim on killing 99.9% of microorganisms.
The proposed framework may encounter diculty for international harmonization. Similar to other health products, such as therapeu­tics, quasi-medicinal products and medical devices, dierences in regulations exist across RAs. Furthermore, a tighter framework adds regulatory burden and redirects resources away from more important domains, such as other higher-risk medicinal products.
423
Training pharmacists on hand sanitizer vigilance
Hand sanitizers may be sold in pharmacies or other retail outlets. In comparison to supermarkets and other general retail outlets, pharmacies are managed under the personal supervision of licensed pharmacists. Hence, pharmacies have been perceived to be ethical retail outlets which oer for sale and supply health products, includ­ing hand sanitizers, that are reliable. Pharmacies should restrict themselves only to the sale of reliable and accurately labelled hand sanitizers to safeguard consumer health. Pharmacists can be trained to possess adequate knowledge on the regulations of antiseptics. This could be performed through the provision of regulatory and international guidelines. The knowledge could be used to identify
424
Manufacture and Supply, Science and Reg ulation Towards High-Qua lity Medicinal Products
inappropriately sold hand sanitizers and pharmacists should be given the autonomy to request for removal of the product from the store. In fact, pharmacists should better educate and address con­sumers’ queries on hand sanitizer eectiveness.
Public Education
Apart from regulation, conscious eorts should be placed on edu­cating the public. Consumers hold misconceptions about hand san­itizers and safety issues have occurred due to the lack of knowledge in this field. Therefore, public education is necessary in collabora­tion with relevant stakeholders [99, 100]. Public education can focus on general hand hygiene, including the myths and benefits of hand sanitizers and the harms of using disinfectant-grade antimicrobial agents interchangeably with antiseptic-grade skin formulations. Additionally, collaborations with pharmacies can be explored. For example, the placement of posters next to sales counters of hand sanitizers can provide a second line of defense to combat consum­ers’ misinformation. Some content could include sharing on the WHO 6 Steps of ‘How to hand- rub’ technique to promote eective use and storage advice to reiterate safety precautions. Collaboration with stakeholders facilitates the education of a wider target group due to the extensivity of outreach. Collaborative education also reduces the burden on regulators.
Conclusion
The multifaceted challenges of safety, eectiveness will grow and hence, regulatory control will continue to evolve with the
Hand Sanitizers
progression of COVID-19 pandemic. This paper has shown that hand sanitizers are assets to hand hygiene, especially during the COVID­19 pandemic, provided they are used properly. Therefore, educat­ing the public on hand sanitizers, including misleading claims and proper use, is crucial. ABHS remain the mainstay as recommended by WHO and other international organizations and should be more tightly regulated due to safety concerns. Future developments can consider the feasibility of international harmonization of regula­tions and explore other standards for testing ecacy that may be more representative of all microorganisms. A tripartite relationship among consumers, regulators and manufacturers should be estab­lished for the ultimate benefit of everyone.
Competing interests: None.
425
Provenance and peer review: Not commissioned; externally peer reviewed.
Authors
Adjunct Associate Professor Sia Chong Hock, BSc Pharm, MSc Tan Ying Ting, BSc Pharm (Hons)
Associate Professor Chan Lai Wah, BSc Pharm (Hons), PhD Department of Pharmacy National University of Singapore 18 Science Drive 4 Singapore 117543
426
Manufacture and Supply, Science and Reg ulation Towards High-Qua lity Medicinal Products
References
This article has 114 references which can be found at https://gabi­journal.net/microbiological-scientific-and-regulatory-perspectives­of-hand-sanitizers.html.
Chapter 14

Pharmaceutical Dosage Forms

427

14.1. Introduction

his chapter on pharmaceutical dosage forms is largely derived from the lectures on Dosage Form Design delivered by the co-author (Professor Chan Lai Wah) to
T
Professor Chan Lai Wah delivering a lecture and receiving Honor Roll (Award) from NUS president
pharmacy undergraduates at the National University of
428
Manufacture and Supply, Science and Reg ulation Towards High-Qua lity Medicinal Products
Singapore (NUS). Over the years, Professor Chan has shared her knowledge and experience with multiple cohorts of students and won numerous awards for her excellence in teaching.

14.2. What Are Pharmaceutical Dosage Forms?

As a patient, consumer or lay person, you may have come across the term “pharmaceutical dosage forms” in some technical mag­azines or newsletters which you have read. Or perhaps, you may have seen these words appearing on the labels or package inserts of the medicinal products which you have been prescribed, or bought over-the-counter (OTC) from pharmacies and drug stores. What do you understand by pharmaceutical dosage forms? Put simply, pharmaceutical dosage forms refer to the dierent presentations of medicinal products. These dierent presentations contain the active pharmaceutical ingredients and excipients which are mixed
Dierent pharmaceutical dosage forms
Pharmaceutical Dosage Forms
together and formulated or “configured”, to facilitate easy adminis­tration and accurate delivery of the active pharmaceutical ingredi­ent(s) to the target receptor sites in the human body.
14.3. Why Are Dierent Pharmaceutical Dosage Forms Needed?
Within the hospital wards, accident and emergency departments, operating theatres as well as medical clinics, pharmacies and drug stores in the community, a whole range of medicinal products in various pharmaceutical dosage forms are stocked for urgent or rou­tine dispensing and supply. These dierent pharmaceutical dosage forms, or simply dosage forms, are needed for a number of reasons such as convenience in consumption by patients, dosing accuracy, portability, as well as solubility and stability of the drug substances. Depending on the age of patients and their ability to adminis­ter medicines by themselves, some dosage forms are preferred to others. Moreover, dierent diseases and medical conditions may warrant dierent routes of administration of the medicinal prod­ucts to the patient. Dosage forms such as tablets, capsules and liquid mixtures are usually taken orally. However, there may be certain medical conditions that make oral consumption highly challeng­ing. For example, persistent nausea, especially with vomiting, may make it unsuitable to use an oral dosage form. In such a case, it is necessary for a doctor or pharmacist to recommend a dosage form which can be administered via an alternative route, such as a suppository which is administered via the anal-rectal route, or an injection which is administered via the parenteral route. Furthere­more, a specific pharmaceutical dosage form may be needed due to other factors such as the chemical stability or pharmacokinetics of
429
430
Manufacture and Supply, Science and Reg ulation Towards High-Qua lity Medicinal Products
the drug substance. A case in point is insulin which cannot be given orally because this hormonal medicine for treating diabetes will be extensively broken down in the gastrointestinal tract (GIT) before reaching the blood stream of the patient, rendering it incapable of reaching its target sites in sucient dose. Furthermore, some drugs when given orally will undergo first-pass metabolism in the liver, rendering them ineective.
In summary, pharmaceutical dosage forms are needed for various purposes, such as, but not limited to, the following examples:
to mask undesirable taste or oensive odor of a drug substance, e.g., capsules, sugar-coated tablets and taste-masked suspensions.
to protect the drug substance from the destructive influence of gastric juice following oral administration of the dosage form, e.g., enteric-coated tablets and film-coated tablets.
to provide drug products that bypass the first-pass metabolism, e.g., injections, topical creams and ointments.
to achieve rapid onset of action following drug delivery, e.g., injections and inhalers.
to provide a suitable dosage form for administering poorly water-soluble or insoluble drugs in an appropriate vehicle, e.g., suspensions.
to provide sterile, clear and particulate-free liquid dosage forms of drug substances, e.g., injections and eye drops.
to provide drug products with a predetermined release rate and therapeutic eect over an extended period of time, e.g., modi­fied-release tablets, capsules and suspensions.
to prevent a drug from being extensively metabolized in the GIT before reaching the blood stream, rendering it incapable of reaching its target destination in sucient dose, e.g., injections.
Pharmaceutical Dosage Forms
to achieve improved bioavailability and drug targeting e.g., solu­tions and nano-formulations.
14.4. How Are Pharmaceutical Dosage Forms
Classified?
Pharmaceutical dosage forms may be classified based on the routes of administration or their physical forms.
14.4.1. Routes of Administration
14.4.1.1. Oral Dosage Forms — Solids
431
Oral dosage forms comprise medicinal products taken via the mouth, following which the drug molecules are absorbed through the epithelia and mucosa of the GIT at varying rates. Oral dosage forms may be in solid or liquid state. Examples of oral solid dosage forms include tablets, capsules, pills, granules and powders. Tablets
Oral solid dosage form